Page last updated: 2024-10-16

carbamates and Viremia

carbamates has been researched along with Viremia in 19 studies

Viremia: The presence of viruses in the blood.

Research Excerpts

ExcerptRelevanceReference
"Owing to the advent of pangenotypic direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) treatment, utilization of HCV-infected deceased donor kidneys with simplified genotyping/subtyping-free sofosbuvir/velpatasvir (SOF/VEL) treatment strategy is now becoming a promising strategy for expanding the organ donor pool."4.12Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China. ( Dai, H; Fang, C; Guo, Y; Hu, S; Lan, G; Liu, Q; Nie, M; Peng, F; Peng, L; Tan, L; Xie, X; Zhang, H; Zhong, M, 2022)
"Amprenavir (APV) is an HIV protease inhibitor (PI) used for the treatment of either naive or PI-experienced HIV-infected patients."3.72Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients. ( Affolabi, D; Bossi, P; Bricaire, F; Calvez, V; Costagliola, D; Delaugerre, C; Katlama, C; Ktorza, N; Lamotte, C; Marcelin, AG; Mohand, HA; Peytavin, G; Voujon, D; Wirden, M, 2004)
" Adverse events (AEs) associated with the study medication occurred in 21% of patients."2.74Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program. ( Luque, I; Mallolas, J; Pérez-Elias, MJ; Rodríguez-Alcántara, F; Sánchez-Conde, M; Soriano, V, 2009)
" The most common adverse events considered to be possibly drug related were nausea, rash, oral paresthesia, diarrhea, and fatigue."2.69A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team. ( Antunes, F; Brown, DJ; Clumeck, N; Fetter, A; Haubrich, R; Kahl, L; Lang, W; Pagano, G; Richman, D; Schooley, R; Sereni, D; Stein, A; Thompson, M; van der Ende, ME, 1999)
" Importantly, adjustments to the immunosuppressant dosage were not required."1.42Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant. ( Achterfeld, A; Canbay, A; Gerken, G; Herzer, K; Papadopoulos-Köhn, A; Paul, A; Timm, J; Walker, A, 2015)

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (10.53)18.2507
2000's8 (42.11)29.6817
2010's6 (31.58)24.3611
2020's3 (15.79)2.80

Authors

AuthorsStudies
Zhang, H1
Liu, Q1
Hu, S1
Zhong, M1
Peng, F1
Guo, Y1
Fang, C1
Nie, M1
Tan, L1
Dai, H1
Xie, X1
Peng, L1
Lan, G1
Terrault, NA1
Burton, J1
Ghobrial, M1
Verna, E1
Bayer, J1
Klein, C1
Victor, D1
Mohan, S1
Trotter, J1
Dodge, J1
Niemann, CU1
Rubin, RA1
Yu, ML1
Huang, CF1
Wei, YJ1
Lin, WY1
Lin, YH1
Hsu, PY1
Hsu, CT1
Liu, TW1
Lee, JJ1
Niu, SW1
Huang, JC1
Hung, TS1
Yeh, ML1
Huang, CI1
Liang, PC1
Hsieh, MY1
Chen, SC1
Huang, JF1
Chang, JM1
Chiu, YW1
Dai, CY1
Hwang, SJ1
Chuang, WL1
Antón, MD1
Polanco, A1
Ferrando, I1
Latorre, P1
Pascual, A1
Moreno Osset, E1
Gottlieb, RL1
Sam, T1
Wada, SY1
Trotter, JF1
Asrani, SK1
Lima, B1
Joseph, SM1
Gonzalez-Stawinski, GV1
Hall, SA1
Teraoka, Y1
Uchida, T1
Imamura, M1
Hiraga, N1
Osawa, M1
Kan, H1
Saito, Y1
Tsuge, M1
Abe-Chayama, H1
Hayes, CN1
Makokha, GN1
Aikata, H1
Miki, D1
Ochi, H1
Ishida, Y1
Tateno, C1
Chayama, K1
Duerr, M1
Schrezenmeier, EV1
Lehner, LJ1
Bergfeld, L1
Glander, P1
Marticorena Garcia, SR1
Althoff, CE1
Sack, I1
Brakemeier, S1
Eckardt, KU1
Budde, K1
Halleck, F1
Herzer, K1
Papadopoulos-Köhn, A1
Walker, A1
Achterfeld, A1
Paul, A1
Canbay, A1
Timm, J1
Gerken, G1
Sankawa, Y1
Pérez-Elias, MJ1
Sánchez-Conde, M1
Soriano, V1
Mallolas, J1
Luque, I1
Rodríguez-Alcántara, F1
Paulsen, D1
Liao, Q1
Fusco, G1
St Clair, M1
Shaefer, M1
Ross, L1
Bogner, JR1
Eberle, J1
Troendle, U1
Goebel, FD1
Marcelin, AG1
Affolabi, D1
Lamotte, C1
Mohand, HA1
Delaugerre, C1
Wirden, M1
Voujon, D1
Bossi, P1
Ktorza, N1
Bricaire, F1
Costagliola, D1
Katlama, C1
Peytavin, G1
Calvez, V1
Khanlou, H1
Bhatti, L1
Farthing, C1
Haubrich, R1
Thompson, M1
Schooley, R1
Lang, W1
Stein, A1
Sereni, D1
van der Ende, ME1
Antunes, F1
Richman, D1
Pagano, G1
Kahl, L1
Fetter, A1
Brown, DJ1
Clumeck, N1
Rizzardi, GP1
De Boer, RJ1
Hoover, S1
Tambussi, G1
Chapuis, A1
Halkic, N1
Bart, PA1
Miller, V1
Staszewski, S1
Notermans, DW1
Perrin, L3
Fox, CH1
Lange, JM1
Lazzarin, A1
Pantaleo, G1
Chang, HE1
Tilling, R1
Kinloch, S1
Goh, LE1
Cooper, D1
Lampe, F1
Zaunders, J1
Hoen, B1
Tsoukas, C1
Andersson, J1
Janossy, G1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Micro-elimination of Hepatitis C Virus Infection With Pan-genotypic DAA Regimen in Hepatitis C Highly Endemic and Contagious Community (ERASE-C)[NCT03891550]Phase 3135 participants (Anticipated)Interventional2019-05-13Active, not recruiting
Comprehensive Surveillance of HCV Infecion in Uremics Under Maintenance Hemodialysis and Linking to Medical Care in Taiwan[NCT03803410]2,973 participants (Actual)Observational2019-01-07Completed
A Phase II Trial to Evaluate the Safety and Efficacy of Induction Treatment With Lamivudine Plus Stavudine Plus Abacavir Plus Amprenavir/Ritonavir Followed by Supervised Treatment Interruption in Subjects With Acute HIV Infection or Recent Seroconversion[NCT00000940]Phase 2121 participants (Actual)Interventional1999-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

6 trials available for carbamates and Viremia

ArticleYear
A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
    BMC nephrology, 2019, 02-04, Volume: 20, Issue:1

    Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Biopsy, Needle; Calcineurin Inhibitors; Carbam

2019
[Complication sequelae prevented, morbidity decreased].
    MMW Fortschritte der Medizin, 2015, Dec-14, Volume: 157, Issue:21-22

    Topics: Carbamates; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Py

2015
Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.
    Enfermedades infecciosas y microbiologia clinica, 2009, Volume: 27, Issue:1

    Topics: Adult; Carbamates; CD4 Lymphocyte Count; Comorbidity; Drug Therapy, Combination; Female; Fever; Fura

2009
Amprenavir in pre-treated patients: virological and immunological response in a cohort of 45 patients.
    European journal of medical research, 2003, Feb-21, Volume: 8, Issue:2

    Topics: Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination

2003
A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.
    AIDS (London, England), 1999, Dec-03, Volume: 13, Issue:17

    Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Female; Furans; HIV Infections; HIV Protea

1999
Therapeutic vaccination in primary HIV infection, the Quest trial.
    Vaccine, 2002, May-06, Volume: 20, Issue:15

    Topics: AIDS Vaccines; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD8-Positive T-Ly

2002

Other Studies

13 other studies available for carbamates and Viremia

ArticleYear
Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China.
    BioMed research international, 2022, Volume: 2022

    Topics: Adult; Antiviral Agents; Carbamates; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chroni

2022
Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors.
    Hepatology (Baltimore, Md.), 2021, Volume: 73, Issue:6

    Topics: Antiviral Agents; Carbamates; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C; Hetero

2021
Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C).
    Gut, 2021, Volume: 70, Issue:12

    Topics: Antiviral Agents; Carbamates; Drug Combinations; Hemodialysis Units, Hospital; Hepatitis C; Heterocy

2021
Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C).
    Gut, 2021, Volume: 70, Issue:12

    Topics: Antiviral Agents; Carbamates; Drug Combinations; Hemodialysis Units, Hospital; Hepatitis C; Heterocy

2021
Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C).
    Gut, 2021, Volume: 70, Issue:12

    Topics: Antiviral Agents; Carbamates; Drug Combinations; Hemodialysis Units, Hospital; Hepatitis C; Heterocy

2021
Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C).
    Gut, 2021, Volume: 70, Issue:12

    Topics: Antiviral Agents; Carbamates; Drug Combinations; Hemodialysis Units, Hospital; Hepatitis C; Heterocy

2021
Hepatitis B reactivation in a patient with chronic hepatitis C treated with direct-acting antivirals.
    Gastroenterologia y hepatologia, 2018, Volume: 41, Issue:5

    Topics: Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Guani

2018
Rational Heart Transplant From a Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan Horse.
    Journal of cardiac failure, 2017, Volume: 23, Issue:10

    Topics: Adult; Antiviral Agents; Carbamates; Drug Combinations; Female; Heart Failure; Heart Transplantation

2017
Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.
    The Journal of general virology, 2018, Volume: 99, Issue:8

    Topics: Animals; Antiviral Agents; Benzazepines; Biomarkers; Carbamates; Drug Combinations; Drug Resistance,

2018
Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant.
    Digestion, 2015, Volume: 91, Issue:4

    Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus

2015
Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
    AIDS research and human retroviruses, 2002, Sep-20, Volume: 18, Issue:14

    Topics: Carbamates; Cross-Sectional Studies; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV P

2002
Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
    Journal of medical virology, 2004, Volume: 74, Issue:1

    Topics: Adult; Amino Acid Substitution; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Femal

2004
Interaction between atazanavir and fosamprenavir in the treatment of HIV-infected patients.
    Journal of acquired immune deficiency syndromes (1999), 2006, Jan-01, Volume: 41, Issue:1

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Drug Adminis

2006
Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.
    The Journal of clinical investigation, 2000, Volume: 105, Issue:6

    Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies

2000
Conference looks at HIV drug resistance.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1995, Volume: 9, Issue:9

    Topics: Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Microbial; Furans; HIV; HIV Inf

1995
Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection.
    AIDS (London, England), 2002, Mar-08, Volume: 16, Issue:4

    Topics: Adult; Anti-HIV Agents; Antigens, CD; Antiretroviral Therapy, Highly Active; Biomarkers; Carbamates;

2002